United Therapeutics Pays $140M Upfront Plus $160M Earn-Out for Thymic Therapy
UTHR•United Therapeutics acquired preclinical-stage Thymmune Therapeutics for $140 million upfront plus up to $160 million in potential earn-out payments tied to 2031 milestones. Thymmune’s iPSC-derived thymic cell therapy candidate THY-100 induced neo-thymus formation in animal studies and targets congenital athymia, transplant tolerance and autoimmune diseases.
1. Acquisition Terms
United Therapeutics has agreed to acquire Thymmune Therapeutics, a preclinical-stage biotech, for $140 million in cash and up to $160 million in earn-out payments contingent on clinical and regulatory milestones through 2031.
2. Thymic Cell Therapy Platform
Thymmune’s proprietary process converts human-induced pluripotent stem cells into functional thymic cells, laying the foundation for regenerative thymic therapies capable of restoring T-cell development.
3. Clinical Implications
In preclinical animal studies, treatment with THY-100 generated a neo-thymus that produced mature T-cells, addressing congenital athymia and potentially enhancing transplant tolerance and autoimmune disease treatments.
4. Strategic Fit
This acquisition bolsters United Therapeutics’ immunomodulatory portfolio and complements its UThymoKidney program by integrating thymic cell therapies to expand its pipeline of organ and immune-based treatments.
